📊 TELO Key Takeaways
Is Telomir Pharmaceuticals, Inc. (TELO) a Good Investment?
Telomir is a pre-revenue stage pharmaceutical company with a healthy but cash-constrained balance sheet facing ~2-year cash runway at current burn rates. While losses improved 37% YoY and debt is minimal, the company generates no revenue and is burning $3.7M annually, making it a clinical development story dependent entirely on pipeline success rather than fundamental business execution.
Why Buy Telomir Pharmaceuticals, Inc. Stock? TELO Key Strengths
- Strong liquidity position with 5.14x current ratio and no meaningful debt burden
- Loss trajectory improving significantly YoY (-10.4M vs prior ~-16.5M implied)
- Stockholders' equity positive at $5.9M with minimal long-term debt of $100K
TELO Stock Risks: Telomir Pharmaceuticals, Inc. Investment Risks
- Pre-revenue company with zero business generation and complete development-stage dependence
- Cash burn of $3.7M annually against total cash of $7.3M implies only ~2 years remaining runway
- Operating cash flow deeply negative with no path to positive cash generation until clinical success and commercialization
Key Metrics to Watch
- Cash burn rate trend and runway adequacy for clinical milestones
- Pipeline advancement progress and clinical trial results
- Capital raise activity and dilution risk to equity holders
Telomir Pharmaceuticals, Inc. (TELO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.14x current ratio provides a solid financial cushion.
TELO Profit Margin, ROE & Profitability Analysis
TELO vs Healthcare Sector: How Telomir Pharmaceuticals, Inc. Compares
How Telomir Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Telomir Pharmaceuticals, Inc. Stock Overvalued? TELO Valuation Analysis 2026
Based on fundamental analysis, Telomir Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Telomir Pharmaceuticals, Inc. Balance Sheet: TELO Debt, Cash & Liquidity
TELO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Telomir Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
TELO Revenue Growth, EPS Growth & YoY Performance
Telomir Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
TELO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Telomir Pharmaceuticals, Inc. (CIK: 0001971532)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TELO
What is the AI rating for TELO?
Telomir Pharmaceuticals, Inc. (TELO) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TELO's key strengths?
Claude: Strong liquidity position with 5.14x current ratio and no meaningful debt burden. Loss trajectory improving significantly YoY (-10.4M vs prior ~-16.5M implied).
What are the risks of investing in TELO?
Claude: Pre-revenue company with zero business generation and complete development-stage dependence. Cash burn of $3.7M annually against total cash of $7.3M implies only ~2 years remaining runway.
What is TELO's revenue and growth?
Telomir Pharmaceuticals, Inc. reported revenue of N/A.
Does TELO pay dividends?
Telomir Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find TELO SEC filings?
Official SEC filings for Telomir Pharmaceuticals, Inc. (CIK: 0001971532) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TELO's EPS?
Telomir Pharmaceuticals, Inc. has a diluted EPS of $-0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TELO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Telomir Pharmaceuticals, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TELO stock overvalued or undervalued?
Valuation metrics for TELO: ROE of -176.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TELO stock in 2026?
Our dual AI analysis gives Telomir Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TELO's free cash flow?
Telomir Pharmaceuticals, Inc.'s operating cash flow is $-3.7M, with capital expenditures of N/A.
How does TELO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -176.1% (avg: 15%), current ratio 5.14 (avg: 2).